

Hypoglycemia:

An unwelcome companion to effective diabetes management

Tailor your assessment, prevention, and treatment to individual patient needs and risks.

By Dana E. Brackney, PhD, RN, CDE, BC-ADM

HYPOGLYCEMIA is generally defined in adults and children with diabetes as a blood glucose (BG) ≤ 70 mg/dL with or without hypoglycemia symptoms. A more comprehensive definition is any drop in BG that exposes a person to harm.

RNs often are the first responders to hypoglycemia, both on the job and in the community. Hypoglycemia is a risk even with effective management and treatment of type 1, type 2, and gestational diabetes. In addition to uncomfortable symptoms, hypoglycemia places people at risk for injury and contributes to an inability to achieve diabetes BG goals. Informed RNs improve patient outcomes by tailoring hypoglycemia assessment, pre-

vention, and treatment to individual needs and potential risks.

Uncontrolled BG

Normal BG regulation occurs when peripheral receptors in the hepatic portal vein and central receptors in the hindbrain and hypothalamus respond to changes in BG and release counter regulatory hormones (glucagon) and neurotransmitters (serotonin, norepinephrine, epinephrine). Together, these hormones and neurotransmitters produce the physical symptoms of hypoglycemia, decrease glucose uptake from peripheral tissues, and activate hepatic glucose production.

Some people with frequent hypoglycemia develop hypoglycemia-as-

sociated autonomic failure (HAAF), resulting in hypoglycemia unawareness, defined as not having any physical symptoms preceding the onset of hypoglycemia. When patients don't have early signs to act upon, hypoglycemia unawareness can lead to severe hypoglycemia (BG < 50 mg/dL) that requires assistance from someone else. Many people can restore hypoglycemia awareness by maintaining a BG above 100 mg/dL for several weeks.

Symptom classification

Accurate knowledge and documentation of hypoglycemia episodes assists with BG pattern identification and acquisition of diabetes supplies. Insurance companies usually require evidence of hypoglycemia severity and frequency to support the need for an insulin pump, continuous glucose monitor (CGM), or increased test strip allowance. Symptoms are classified and documented by target tissue (neurogenic or neuroglycopenic) and timing (fasting or postprandial). BG results combined with these symptoms provide additional evidence of hypoglycemia patterns. (See *Symptom classification*.)

Target tissue

Neurogenic (sympathetic) symptoms of hypoglycemia include perspiration, tremor, rapid heartbeat, anxiety, and hunger. Neuroglycopenic symptoms include weakness, tired-



Symptom classification

Hypoglycemia symptoms are classified based on target tissue (neurogenic or neuroglycopenic) and timing (fasting or postprandial).

Target Tissue

Neurogenic	Neuroglycopenic
Perspiration	Weakness
Tremor	Fatigue
Rapid heart rate	Dizziness
Anxiety	Visual changes
Hunger	Inappropriate behavior
	Coma

Timing

Fasting	Postprandial
Nocturnal	Related to medication timing or dose
Missed or delayed meal	Related to meal composition
	Related to activity; symptoms typically occur 2 to 4 hours after eating a meal

ness, or dizziness; inappropriate behavior; inability to concentrate; confusion; blurred vision; and, in extreme cases, coma and death. Others may mistake the person with neuroglycopenia as being under the influence of alcohol or drugs. Advise patients with diabetes to wear medical alert information to decrease the likelihood of mistreatment.

Timing

Fasting hypoglycemia appears during sleep or after a prolonged period of not eating. Postprandial hypoglycemia typically occurs 2 to 4 hours after eating a meal. Assess and document these symptoms and time periods to identify BG patterns and guide hypoglycemia prevention and treatment strategies.

Patient-centered assessment

A patient-centered assessment will aid in individualizing prevention

and treatment. Ask patients about their hypoglycemia history and risk factors and how they assess BG.

Hypoglycemia history

Discuss hypoglycemia history with all patients who have type 1, type 2, or gestational diabetes regardless of their HbA1c levels. Review the patient's medication history; commonly prescribed cardiac medications such as beta blockers and warfarin increase the risk for hypoglycemia unawareness. Your goal is to identify common situations that increase hypoglycemia risk, such as exercise, alcohol use, and meals that are poorly timed with medication type and/or dosage. (See *Hypoglycemia history*.)

BG assessment

Patients can assess their BG with a glucometer or a CGM that also requires periodic glucometer checks.

These tools have improved patients' ability to self-manage their diabetes.

Glucometers measure capillary BG via blood obtained with a fingerstick. They provide a single data point, so patients can only respond to the information obtained at that time.

CGMs go a step further by helping patients anticipate possible hypoglycemia (and hyperglycemia). CGMs consist of a sensor and a receiver. The patient uses a removable needle to place the flexible sensor under the skin. Every few minutes, the sensor measures glucose in the interstitial fluid and transmits the data wirelessly to a receiver, which might be a monitor carried in a pocket or purse, or a smartphone or tablet. The frequent sampling establishes trends that help predict the direction and rate of BG change. Patients also can note meals, physical activities, and medications to provide additional data that help in analyzing trends. The sensor need to be replaced every 3 to 7 days, depending on the device.

Understanding the limitations of glucometers and CGMs will help you facilitate accurate hypoglycemia assessment.

Glucometer malfunction is relatively rare; erroneous results usually are related to blood sampling technique or test strip exposure to heat or moisture. In addition, glucometers perform with up to a 15% margin of error. At the low end of the BG scale, this makes a clinical difference in treatment decisions.

CGM reliability depends on twice-daily calibrations with capillary BG checks. Due to variable measurement between capillary and venous blood samples, many hospital protocols require BG confirmation with a venous sample at the time of hypoglycemia treatment.

Despite these caveats, BG monitoring remains a cornerstone of hypoglycemia prevention and diabetes self-management.

Hypoglycemia history

The goal of a hypoglycemia history is to determine what circumstances or situations increase a patient's hypoglycemic risk.

Question	Rationale
When was the last time you had low blood sugar?	People may report hypoglycemia that happened years ago, but this question determines if hypoglycemia is a current problem.
How low was your reading?	Some people treat blood glucose (BG) based on how they feel without checking their BG. Establish the BG level at which people feel hypoglycemia. Neurogenic symptoms may occur without a drop in BG.
How often and when does this happen?	Hypoglycemia pattern recognition guides prevention.
What do you think caused the low blood sugar?	The patient's understanding guides treatment and prevention or identifies a knowledge gap.
How did you treat the low blood sugar?	The patient's answer reveals knowledge gaps and overtreatment that interferes with HbA1c goal achievement.
What fears or concerns do you have about low blood sugar?	Fear is common among people with both type 1 and type 2 diabetes, and it impedes HbA1c goal achievement.
Have you ever needed help due to severe low blood sugar (< 50 mg/dL)?	The answer will identify people at serious risk for low BG and guide self-management interventions.

Risk identification

Risk for hypoglycemia depends on patient behaviors—particularly as they relate to timing of meals and medications—age, and type of diabetes medication.

Patient-behavior challenges to hypoglycemia prevention include erratic schedules, disordered eating, and exercise without medication and meal adjustments. A common cause of hypoglycemia is an imbalance between a medication's onset of action and its administration related to a meal's timing or composition. In addition, the timing and intensity of physical activity contributes to hypoglycemia.

Age-related physical changes place some people at greater risk for hypoglycemia. For example, growth hormone fluctuations, neurotransmitter aging, gastroparesis,

and decreased kidney and liver function all impact glucose regulation.

Most diabetes medications carry some risk for hypoglycemia; however, some have a higher risk than others due to their mechanism of action or fixed dose ratio. For example, people are more likely to experience hypoglycemia if they use sulfonylureas (glyburide, glipizide), meglitinides (repaglinide), or premixed insulins (70/30 NPH/R or 70/30 NPH/lispro). Rapid-acting and short-acting insulin contribute to hypoglycemia risk more than long-acting insulin because of their different pharmacodynamics. Hypoglycemia risk frequently coincides with the peak effect of insulin. The onset, peak effect, and duration of rapid-acting insulin is < 15 minutes, 30 to 90 minutes, and 3 to 5 hours, respectively. Short-acting insulin

has an onset of 0.5 to 1 hour, peak effect of 2 to 4 hours, and a duration of 4 to 8 hours. In contrast, long-acting insulin begins working in 1 to 2 hours, has no peak effect, but has a duration of up to 24 hours.

Prevention

Hypoglycemia prevention is preferred to hypoglycemia treatment for achieving diabetes management goals. Hypoglycemia indirectly contributes to HbA1c elevation because of the hyperglycemia that often follows overtreatment with carbohydrate. In addition, fear of hypoglycemia can prevent patient adherence to medication dosages or even prevent prescribing glucose-lowering medications. Both overtreatment of hypoglycemia and aversion to diabetes medications may worsen diabetes control.

Design prevention strategies based on each person's unique experience with hypoglycemia. For example, people with diabetes can prevent hypoglycemia by decreasing their diabetes medication dose before physical activity or by eating more in anticipation of activity. Insulin pump users can decrease basal insulin before, during, or after exercise. Likewise, they can decrease the rapid-acting insulin dose at the meal that precedes activity.

Each patient-care setting presents unique challenges for hypoglycemia prevention and treatment. (See *Hypoglycemia prevention challenges*.) Advocate for implementation of prevention strategies in your care setting. You and the diabetes management team can create practical solutions. (See *Hypoglycemia prevention strategies*.)

Treatment

Adopt evidence-based hypoglycemia treatment protocols for use in acute-care, long-term care, home, and school settings. Consider hypoglycemia a critical incident and evaluate its frequency in your care setting and the treatment protocol's

Hypoglycemia prevention challenges

Each care setting presents unique hypoglycemia prevention challenges and coinciding nursing considerations. Below are some examples.

Setting	Prevention challenges	Nursing considerations
Hospital	<ul style="list-style-type: none"> • Antidiabetic medication orders don't match the patient's home medication administration behavior. • Hospital stress contributes to hypoglycemia. • Decreased kidney function increases duration of insulin action. 	<ul style="list-style-type: none"> • Assess the patient's home medication behaviors. Timing and dosing may be quite different than prescribed. • Physical and emotional stress of hospitalization may require diabetes medication changes (type, dose, or timing). • Anticipate reduction in insulin dosages with decreased renal function.
Long-term care	<ul style="list-style-type: none"> • Division of care responsibilities may increase risk for hypoglycemia when a sudden change in eating behavior isn't accompanied by a medication adjustment. 	<ul style="list-style-type: none"> • Develop policies that allow administration of insulin or oral agent immediately after meal consumption to prevent hypoglycemia.
Home	<ul style="list-style-type: none"> • Daytime lows. Some people report always feeling hungry or being very sensitive to changes in blood glucose (BG) levels. • Nighttime lows. Periodic 3 AM BG checking or use of continuous glucose monitor is needed to assess nighttime BG. 	<ul style="list-style-type: none"> • Add daily psyllium fiber or uncooked cornstarch products to stabilize BG over 4 hours, day or night. • With prescriber approval, consider adjusting basal insulin to prevent nighttime lows.
Community	<ul style="list-style-type: none"> • Patient reports hypoglycemia only on Sundays when attending church, during stop-and-go activities like golfing and bowling, and on workdays that have unpredictable breaks. • Students in school may lack access to snacks and age-appropriate guidance related to the timing of snacks. 	<ul style="list-style-type: none"> • With prescriber approval, instruct patient to reduce mealtime insulin (by 30%-50%) or to decrease oral agent dosage if BG drops on specific days, in specific settings, or with specific activities. • With prescriber approval, work with the student and school to adjust medication for certain activities, such as physical education, to prevent low BG. • Provide school personnel with written instructions on day-to-day medication adjustments to prevent hypoglycemia.

effectiveness. Base treatment protocols on the patient's condition (conscious, I.V. access, NPO status) and BG level. The patient's condition will guide whether a meal, oral glucose, I.V. dextrose, or glucagon is appropriate treatment. Follow protocol instructions for ongoing BG monitoring and evaluation of treatment effectiveness (for example, see this protocol from the American Association of Clinical Endocrinologists: inpatient.aace.com/protocols-and-order-sets).

A meal

For a balance of short- and long-act-

ing fuel that maintains body functions, patients with mild hypoglycemia that occurs at mealtimes should eat a meal that contains complex carbohydrates, protein, fats, fiber, and simple sugars. Instruct patients taking mealtime diabetes medications to follow prescribed dosage adjustments before a meal when BG is < 100 mg/dL. For example, they may decrease their insulin dose 25% to 50%. Omitting insulin completely at mealtime contributes to subsequent hyperglycemia. Provide patients with specific written instructions for common BG scenarios to build their self-management confi-

dence. It's important not to over-treat hypoglycemia. For instance, consuming more than 15 to 20 g of carbohydrate in response to hypoglycemia causes hyperglycemia.

Oral glucose

Oral glucose elevates BG in about 15 minutes. Instruct patients to use measured hypoglycemia treatments such as instant glucose, chewable glucose tablets, or 4 oz to 6 oz of regular soda. The carbohydrate dose is 15 g to 20 g for adults and weight based for children (generally 200 mg/kg). Using glucose is especially important for patients taking

Hypoglycemia prevention strategies

Within your care setting, work with the diabetes management team to advocate for, develop, and implement hypoglycemia prevention strategies based on individual patient needs. Here are some examples.

Patient characteristics	Prevention strategies
Young patient with type 1 diabetes whose carbohydrate/meal consumption is erratic	<ul style="list-style-type: none"> • Administer rapid-acting insulin immediately after the meal.
School-age patient with type 1 diabetes with erratic activity related to recess or physical education (PE)	<ul style="list-style-type: none"> • Provide a cornstarch-based snack bar as a steady source of carbohydrate before activity and at bedtime. • Consider reducing lunchtime insulin for afternoon recess and PE.
Adolescent patient with type 1 diabetes experiencing rapid growth	<ul style="list-style-type: none"> • Increase blood glucose (BG) goal and reduce total daily dose of insulin. • Explain to patient that he or she hasn't done anything wrong.
Adolescent patient with type 1 diabetes who plays competitive sports	<ul style="list-style-type: none"> • Check BG before, during (every 30 min), and after (2-12 hours) activity. • Eat before activity and reduce insulin dosage. • Have glucose available during exercise and use a cornstarch-based snack bar before bed to prevent nighttime hypoglycemia.
Young adult patient with type 1 diabetes adjusting to workplace break limitations	<ul style="list-style-type: none"> • Eat a meal and cornstarch-based snack bar before work to prevent lows. • Adjust insulin to achieve BG goals.
Adult with type 2 diabetes who requires insulin but objects to administering it in public and injects rapid-acting mealtime insulin before driving to a restaurant.	<ul style="list-style-type: none"> • Discuss private options for taking insulin after arriving at a restaurant (such as in the parking lot or bathroom).
Adult or older adult patient with type 2 diabetes using an oral secretagogue antidiabetic agent	<ul style="list-style-type: none"> • Decrease dose and/or change medication timing based on daily activity. • Consider other medication options, such as basal insulin based on BG profile.
Older adult patient who requires insulin has decreased gastric motility	<ul style="list-style-type: none"> • Change from rapid- to short-acting regular insulin before meals or administer rapid-acting insulin after meals.

acarbose or miglitol. These starch-blocking medications slow absorption of complex carbohydrates and delay BG elevation.

Glucose deprivation in the brain inhibits clear thinking, so instruct patients to set a timer after BG treatment to overcome the natural instinct to overeat. Family and friends often force overeating because of hypoglycemia fears. To help family members understand and trust the treatment protocols, include them in the hypoglycemia treatment plan.

I.V. dextrose

I.V. dextrose, which is available in a prefilled 50-mL syringe, elevates

BG immediately. It's administered as 50% (D50W) by I.V. push to hospitalized patients with I.V. access who are unable to take an oral hypoglycemia treatment. Give half of a syringe or a whole syringe based the patient's BG level and as directed by the standing orders.

Glucagon

Glucagon elevates BG by stimulating the liver to convert stored glycogen to glucose. In severe hypoglycemia, administer glucagon as a 1-mg intramuscular injection to an unconscious person without I.V. access. Vomiting is a common side effect, so instruct caregivers to place the person on his or her left side af-

ter injecting the glucagon. BG elevation continues for about 1 hour after administration. To maintain normal BG, the patient must eat a meal after regaining consciousness.

Confirm an emergency glucagon kit prescription for all patients with type 1 diabetes, those with a history of severe hypoglycemia, and those at risk for severe hypoglycemia. Teach caregivers how to administer the glucagon injection, and instruct patients and their family to keep the kit easily accessible. Living situations change, so each year identify all friends and family members who need the glucagon information.

(Continued on page 13)